Background

Posterior capsular opacification (PCO) is the most common postoperative complication after cataract surgery, occurring in > 25% of adults. To combat this disease, new and more targets and drugs are still urgently needed. Plantamajoside (PMS) is a natural compound extracted from planajoside and has a wide range of biological activities. However, the role and effects of PMS in PCO are still unclear.

Objectives

To uncover the possible effects of plantamajoside (PMS) on posterior capsular opacification (PCO) progression and clarify the mechanism.

Results

PMS inhibited the proliferation of hLECs. PMS inhibited the autophagy of hLECs. Furthermore, PMS suppressed the motility and EMT of hLECs induced by TGFβ2. PMS suppressed the TGFβ2-induced inflammation of hLECs. Mechanically, PMS restrained the AGEs–RAGE axis, therefore, inhibiting PCO progression.

Conclusion

PMS could serve as a promising drug for PCO treatment.

中文翻译：

---

Plantamajoside 可改善人晶状体上皮细胞中 TGFβ2 诱导的自噬、上皮间质转化和炎症过程

背景

后囊膜混浊 (PCO) 是白内障手术后最常见的术后并发症，发生率 > 25% 的成年人。为了对抗这种疾病，仍然迫切需要新的、更多的靶点和药物。 Plantamajoside (PMS) 是从车前草苷中提取的天然化合物，具有广泛的生物活性。然而，PMS 在 PCO 中的作用和影响仍不清楚。

目标

揭示植物黄苷 (PMS) 对后囊膜混浊 (PCO) 进展的可能影响并阐明其机制。

结果

PMS 抑制 hLEC 的增殖。 PMS 抑制 hLEC 的自噬。此外，PMS 抑制 TGFβ2 诱导的 hLEC 运动和 EMT。 PMS 抑制 TGFβ2 诱导的 hLEC 炎症。从机制上讲，PMS 抑制 AGEs-RAGE 轴，因此抑制 PCO 进展。

结论

PMS 可以作为治疗 PCO 的有前途的药物。